Abstract
There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.
| Original language | English |
|---|---|
| Pages (from-to) | 71-73 |
| Number of pages | 3 |
| Journal | Journal of Clinical Neuroscience |
| Volume | 38 |
| DOIs | |
| Publication status | Published - 1 Apr 2017 |
Fingerprint
Cite this
}
Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG. / Zhou, Yifan; Huang, Qiao; Lu, Tingting; Sun, Xiaobo; Fang, Ling; Lu, Zhengqi; Hu, Xueqiang; Kermode, Allan; Qiu, Wei.
In: Journal of Clinical Neuroscience, Vol. 38, 01.04.2017, p. 71-73.Research output: Contribution to journal › Article
TY - JOUR
T1 - Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG
AU - Zhou, Yifan
AU - Huang, Qiao
AU - Lu, Tingting
AU - Sun, Xiaobo
AU - Fang, Ling
AU - Lu, Zhengqi
AU - Hu, Xueqiang
AU - Kermode, Allan
AU - Qiu, Wei
PY - 2017/4/1
Y1 - 2017/4/1
N2 - There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.
AB - There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.
KW - Azathioprine
KW - MOG-IgG
KW - Multiple sclerosis
KW - Pediatric
UR - http://www.scopus.com/inward/record.url?scp=85009759051&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2016.12.022
DO - 10.1016/j.jocn.2016.12.022
M3 - Article
VL - 38
SP - 71
EP - 73
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
SN - 0967-5868
ER -